 |
Previous Article | Next Article 
The Journal of Neuroscience, November 1, 1998, 18(21):8648-8659
The Localization of the Brain-Specific Inorganic Phosphate
Transporter Suggests a Specific Presynaptic Role in Glutamatergic
Transmission
Elizabeth E.
Bellocchio1,
Hailan
Hu1,
Alicia
Pohorille2,
June
Chan2,
Virginia M.
Pickel2, and
Robert H.
Edwards1
1 Departments of Neurology and Physiology, Graduate
Programs in Neuroscience and Cell Biology, University of California San
Francisco School of Medicine, San Francisco, California 94143, and
2 Department of Neurology and Neuroscience, Cornell
University Medical College, New York, New York 10021
 |
ABSTRACT |
Molecular cloning has recently identified a vertebrate
brain-specific Na+-dependent inorganic phosphate
transporter (BNPI). BNPI has strong sequence similarity to EAT-4, a
Caenorhabditis elegans protein implicated in
glutamatergic transmission. To characterize the physiological role of
BNPI, we have generated an antibody to the protein. Immunocytochemistry
of rat brain sections shows a light microscopic pattern that is
suggestive of reactivity in nerve terminals. Excitatory projections are
labeled prominently, and ultrastructural analysis confirms that
BNPI localizes almost exclusively to terminals forming asymmetric
excitatory-type synapses. Although BNPI depends on a
Na+ gradient and presumably functions at the plasma
membrane, both electron microscopy and biochemical fractionation show
that BNPI associates preferentially with the membranes of small
synaptic vesicles. The results provide anatomic evidence of a specific presynaptic role for BNPI in glutamatergic neurotransmission, consistent with the phenotype of eat-4 mutants. Because
an enzyme known as the phosphate-activated glutaminase produces
glutamate for release as a neurotransmitter, BNPI may augment
excitatory transmission by increasing cytoplasmic phosphate
concentrations within the nerve terminal and hence increasing glutamate
synthesis. Expression of BNPI on synaptic vesicles suggests a mechanism
for neural activity to regulate the function of BNPI.
Key words:
inorganic phosphate transport; BNPI; synaptic vesicle; asymmetric synapse; excitatory neurotransmission; glutamate release
 |
INTRODUCTION |
Neurons exhibit multiple transport
activities that contribute to synaptic transmission. Reuptake across
the plasma membrane terminates the action of classical
neurotransmitters in the synaptic cleft, and transport into synaptic
vesicles packages the transmitter for subsequent release by exocytosis.
Neurons also actively transport a number of compounds and ions not
generally considered to participate directly in signaling. These ions
include inorganic phosphate (Pi), which has been
found to accumulate in both squid and frog neurons (Mullins, 1954 ;
Caldwell and Lowe, 1970 ). More recent studies show that cortical
neurons, cerebellar granule cells, and synaptosomes prepared from the
rat also demonstrate Pi transport, and this activity
depends on a Na+ gradient (Ni et al., 1994 ; Glinn et
al., 1995 ; Furman et al., 1997 ). Although Pi transport has
been observed in these systems, the biological role of Pi
uptake by neurons remains unknown.
In the kidney, Na+-dependent Pi
transport is essential for the maintenance of phosphate homeostasis
(for review, see Murer and Biber, 1996 ). Renal brush-border epithelial
cells of the proximal tubule exhibit Na+-dependent
reabsorption of Pi that is controlled by both hormonal and
nonhormonal mechanisms. The proteins that mediate renal Pi transport activity belong to a family of
Na+/Pi cotransporters that includes
liver as well as kidney isoforms (Werner et al., 1991 ; Li and Xie,
1995 ). Interestingly, a sequence induced by subtoxic levels of
NMDA in cerebellar granule cells also belongs to this family of
transport proteins (Ni et al., 1994 ). Analysis of the mRNA shows that
the expression of this sequence is restricted to the brain and, in
particular, to neurons (Ni et al., 1994 ). Injection of mRNA for this
brain-specific Na+-dependent Pi
transporter (BNPI) into Xenopus oocytes confirms that BNPI
transports Pi in a Na+-dependent manner
(Ni et al., 1994 ). BNPI therefore may contribute to the
Na+-dependent Pi transport activity
observed in cultured primary cortical neurons, cerebellar granule
cells, and synaptosomes prepared from rat brain (Glinn et al., 1995 ;
Furman et al., 1997 ).
Although Na+-dependent Pi uptake may act
simply to replenish ATP stores, a function that presumably would be
required for all neuronal populations, in situ hybridization
indicates that the expression of BNPI mRNA is restricted to a subset of
neurons, including cortical cells, hippocampal pyramidal cells, granule cells of the dentate gyrus, and cerebellar granule cells (Ni et al.,
1995 ), neurons that all use glutamate as a neurotransmitter. This
restricted pattern of BNPI mRNA expression supports a function for BNPI
specific to glutamatergic neurons. Moreover, BNPI shows strong sequence
similarity to EAT-4, a Caenorhabditis elegans protein that
appears to have a specific presynaptic role in glutamatergic transmission (Avery, 1993 ; Dent et al., 1997 ; Li et al., 1997 ; R. Y. N. Lee, E. R. Sawin, M. Chalfie, H. R. Horvitz, and
L. Avery, unpublished observations).
To assess the physiological role of BNPI, we have generated a
polyclonal antibody to the protein and used it to determine the
location of the transporter in the rat brain. At the light microscopic
level, immunocytochemistry shows that BNPI localizes to nerve terminals
that release glutamate as a neurotransmitter. Consistent with a role
for BNPI in excitatory transmission, electron microscopic
immunolabeling shows that BNPI localizes predominantly to axon
terminals at asymmetric synapses. The results thus provide anatomical
evidence of a specific presynaptic role for BNPI in glutamatergic
transmission, as suggested by the phenotype of eat-4 mutants. Further, although the Na+ dependence of
BNPI suggests that BNPI functions at the plasma membrane, electron
microscopic immunolabeling indicates that the majority of BNPI resides
on synaptic vesicles. Biochemical analysis by differential
centrifugation and velocity gradient fractionation confirms this
localization, raising the possibility that exocytosis induced by neural
activity may regulate BNPI function at the plasma membrane.
 |
MATERIALS AND METHODS |
BNPI-pGEX-3X plasmid construction and expression. The
pGEX bacterial expression system (Pharmacia Biotech, Alameda, CA) was used to produce a glutathione S-transferase (GST) fusion
protein containing the last 68 amino acids (residues 493-560) of rat
BNPI (Ni et al., 1994 ). First, the 3' end of the protein coding region (nucleotides 1600-1806) was amplified from BNPI cDNA, using PCR and primers (5'-CGCGGATCCTGGAGAAACAGCCGTGGGCAGAG and
5'-CGGAATTCTCAGTAGTCCCGGACAGGGGGTGG) engineered to
contain BamHI and EcoRI sites that facilitate
subcloning into pGEX-3X. To produce the fusion protein, we induced
Escherichia coli expressing the recombinant plasmid with
isopropyl -D-thiogalactoside (IPTG) for ~4 hr at room
temperature (RT) and then sonicated it. The fusion protein was purified
by chromatography over glutathione Sepharose (Pharmacia Biotech).
Polyclonal antibody production. Two female New Zealand white
rabbits were immunized with the GST-BNPI fusion protein. First, the
animals were inoculated intradermally with ~200 µg of fusion protein emulsified in Freund's complete adjuvant, and then they were
boosted 4 weeks later by a subcutaneous injection of ~100 µg of
fusion protein emulsified in Freund's incomplete adjuvant. Blood was
obtained 9 and 14 d after the boost. The serum was adsorbed with
rat liver acetone powder (LAP; Cappel, Organon Teknika, West Chester,
PA) to reduce nonspecific immunoreactivity.
Cell transfection and membrane preparation. Rat BNPI cDNA in
pcDNA I/Amp (Invitrogen, San Diego, CA) was transfected into COS1 cells
by electroporation (Finn and Edwards, 1997 ). Briefly, COS1 cells grown
in DMEM containing 10% Cosmic calf serum (HyClone Laboratories,
Logan, UT) were harvested and then electroporated at 0.4 kV and 960 µF with 15 µg of DNA. At 3 d after electroporation the
transfected COS cells were harvested, resuspended in 200 µl of buffer
A [(in mM) 150 NaCl, 50 Tris-HCl, 5 EGTA, and 10 EDTA, pH
7.4 on ice] containing protease inhibitors [(in µg/ml) 1 E64, 2 leupeptin, 2 pepstatin, 20 PMSF], and disrupted in a water bath sonicator. Cell debris was removed by sedimentation at 1300 × g for 5 min at 4°C.
Western analysis. Equal amounts of protein were loaded into
each lane, except in the case of velocity sedimentation through glycerol, in which case equal volumes from each fraction were loaded.
In all cases the proteins were separated by electrophoresis via 10%
SDS-polyacrylamide and transferred to nitrocellulose. The
nitrocellulose membranes were blocked in PBS containing 0.1% Tween-20
and 5% nonfat dry milk and then incubated with the relevant primary
antibody in PBS containing 0.1% Tween-20 and 1% nonfat dry milk
(PBS-TM) for 2 hr at RT or overnight at 4°C. BNPI was detected with a
1:2000 dilution of the C-terminal polyclonal antibody preadsorbed with
LAP. Synaptophysin was detected with a monoclonal antibody (clone
SVP-38; Sigma, St. Louis, MO) at a dilution of 1:5000, syntaxin with a
monoclonal antibody (clone HPC-1; Sigma) at 1:2000, and the
Na+/K+ ATPase 1
subunit with a polyclonal antibody (Upstate Biotechnology, Lake Placid,
NY) at 1:1000. After incubation with primary antibody the blots were
washed three times in PBS-TM, incubated for 45 min in PBS-TM containing
a 1:2000 dilution of the appropriate secondary antibody conjugated to
horseradish peroxidase (Amersham, Arlington Heights, IL), and washed in
PBS containing 0.1% Tween-20. The deposits were detected by enhanced
chemiluminescence (Pierce, Rockford, IL).
Preparation of brain extracts. The brains of adult male
Sprague Dawley rats were removed after decapitation and homogenized for
10 strokes at ~750 rpm in cold buffer B [(in mM) 50 Tris-HCl, pH 7.4, 5 EGTA, and 10 EDTA] containing protease inhibitors
[(in µg/ml) 2 aprotinin, 1 E64, 2 leupeptin, 2 pepstatin, and 20 PMSF] by using a Wheaton glass/Teflon homogenizer (clearance 0.1-0.15 mm; Fisher Scientific, Santa Clara, CA). Cell debris was removed from
this homogenate by centrifugation at 1075 × gmax in a Sorvall SS34 rotor (DuPont, Newtown,
CT) for 20 min at 4°C and was resuspended in buffer B with protease
inhibitors to yield the pellet P1. The postnuclear supernatant (PNS)
was sedimented at 152,000 × gmax in an
SW41 rotor (Beckman, Palo Alto, CA) for 1 hr at 4°C. After the
addition of protease inhibitors the resulting high-speed supernatant (HSS1) was centrifuged again under the same conditions to ensure the
removal of all membranes from the supernatant. The resulting second
high-speed supernatant (HSS2) also was supplemented with protease
inhibitors. The high-speed pellets from both centrifugations were
resuspended in buffer B with protease inhibitors and pooled to yield a
high-speed pellet fraction (HSP).
Preparation of kidney extracts. The kidneys were removed
from an adult male Sprague Dawley rat, frozen on liquid nitrogen, and
crushed to a fine powder on dry ice. After its addition to 0.32 M sucrose and 10 mM HEPES, pH 7.4 [containing
5 mM Mg-EGTA, 0.4 µM
diisopropylfluorophosphate (DFP), and (in µg/ml) 2 aprotinin, 2 E64,
5 leupeptin, and 2 pepstatin], the mixture was homogenized at ~750
rpm for 12 strokes in a Wheaton glass/Teflon homogenizer (clearance
0.1-0.15 mm; Fisher Scientific), and the cell debris was removed by
centrifugation at 1600 × g for 10 min at 4°C.
Synaptosome preparation. Synaptosomes were prepared by
standard methods (Huttner et al., 1983 ) with minor modifications.
Briefly, the cerebral cortices of male Sprague Dawley rats were
homogenized in cold buffer C (0.32 M sucrose, 4 mM HEPES-NaOH, pH 7.4, and 1 mM EGTA)
containing protease inhibitors [(in µg/ml) 2 aprotinin, 1 E64, 2 leupeptin, 2 pepstatin, and 20 PMSF] by 10 strokes at 900 rpm in a
Kontes number 22 glass/Teflon homogenizer (clearance 0.13-0.18 mm;
Fisher Scientific) at 4°C. The homogenate was centrifuged in an SS34
rotor (DuPont) for 10 min at 1000 × gmax
to yield a pellet (P1) and a supernatant (S1). P1 was resuspended in
buffer C with protease inhibitors and EGTA. Then S1 was centrifuged at 12,000 × gmax in an SS34 rotor for 15 min.
The resulting supernatant (S2) was removed. The pellet (P2) was washed
by being resuspended in buffer C containing protease inhibitors and
then was centrifuged at 14,500 × gmax for
15 min to yield a supernatant (S2') and pellet (P2'). P2', the crude
synaptosomal fraction, was resuspended in buffer C containing protease
inhibitors, transferred to a Kontes number 22 glass/Teflon homogenizer
(clearance 0.13-0.18 mm), mixed by inversion with 9 vol of cold water
containing 1 mM EGTA and protease inhibitors, and
immediately disrupted by three strokes of homogenization at 3000 rpm.
HEPES-NaOH, pH 7.4, was added to a final concentration of 8.5 mM, and the mixture was centrifuged at 33,000 × gmax in an SS34 rotor for 20 min to yield a
lysate pellet (LP1) and lysate supernatant (LS1). LP1 was resuspended in a 1:10 dilution of buffer C containing protease inhibitors and
HEPES-NaOH, pH 7.4 (final concentration 8.5 mM). Protease inhibitors then were added to LS1, and this fraction was centrifuged at
251,500 × gmax in a 70.1 Ti rotor
(Beckman) for 2 hr to yield a supernatant (LS2) and pellet (LP2). LP2
was resuspended in 40 mM sucrose containing 1 mM EGTA and protease inhibitors.
Glycerol velocity sedimentation. Velocity sedimentation
through glycerol was performed by the procedure of Clift-O'Grady et al. (1990) with minor modifications. Glycerol gradients (5-25%) were
prepared in (in mM) 10 HEPES-NaOH, pH 7.4, 150 NaCl, 1 EGTA, and 0.1 MgCl2 with protease inhibitors [(in µg/ml)
2 aprotinin, 1 E64, 2 leupeptin, 2 pepstatin, and 20 PMSF] over a pad
of 2 M sucrose. LS1 samples (~130 µg), containing
intraterminal components such as synaptic vesicles (Huttner et al.,
1983 ), were layered onto the glycerol gradients and centrifuged at
195,600 × gmax in an SW 50.1 rotor
(Beckman) for 1 hr at 5°C. Fractions were collected from the top of
the gradient.
Immunohistochemistry. Adult male Sprague Dawley rats were
anesthetized and perfused with PBS, followed by 4% paraformaldehyde in
PBS. The brains were dissected, immersed in the same fixative overnight
at 4°C, cryoprotected in 30% sucrose at 4°C, and sectioned at 40 µm on a freezing microtome. Floating brain sections were incubated in
PBS containing 1% normal goat serum (NGS) and 0.3% Triton X-100 (wash
buffer) for 30 min, rinsed, incubated in PBS containing 0.3%
H2O2 for 30 min, rinsed, blocked for 1.5 hr in PBS containing 3% NGS and 0.3% Triton X-100, and incubated overnight at 4°C in wash buffer containing a 1:2000 dilution of primary BNPI
antibody preadsorbed with LAP. To confirm the specificity of the
reaction, we included 10 µg of either GST-BNPI or the control fusion
protein GST-VGAT (Chaudhry et al., 1998 ) in the preadsorption of the
BNPI antiserum with LAP. The sections were washed, incubated for 30 min
at RT with biotinylated goat anti-rabbit secondary antibody (Vector,
Burlingame, CA) diluted 1:200, washed again, and incubated in a 1:400
dilution of avidin-biotin complex conjugated to horseradish peroxidase
(Vector) for 30 min. After being washed, the peroxidase reaction was
visualized with 3,3'-diaminobenzidine and H2O2
and 0.27% NiSO4 to enhance the reaction. Sections were dehydrated in graded ethanols and xylene and then coverslipped with
Permount (Fisher Scientific).
Electron microscopy. The methods for tissue preparation and
immunocytochemical labeling were based on those of Leranth and Pickel
(1989) . Adult male Sprague Dawley rats were anesthetized with sodium
pentobarbital (50 mg/kg, i.p.) and perfused in rapid succession with
(1) 10 ml of phosphate buffer (PB), pH 7.4, containing 1000 U/ml
heparin and 0.15 M NaCl; (2) 50 ml of 3.75% acrolein and
2% paraformaldehyde in PB; and (3) 200 ml of 2% paraformaldehyde in
PB. The brains were removed and post-fixed in 2% paraformaldehyde for
30 min and then sectioned at 40 µm coronal sections with a Lancer
Vibratome. Sections of tissue through forebrain regions were incubated
for 30 min in PB containing 1% sodium borohydride. Then all sections
were cryoprotected for 15 min in 0.05 M PB containing 25%
sucrose and 3.5% glycerol, rapidly frozen in chlorodifluoromethane followed by liquid nitrogen, and thawed in PB at RT. The free-floating tissue sections were incubated overnight at RT in 0.1% bovine serum
albumin (BSA)-Tris saline (TS; 0.9% NaCl in 0.1 M Tris, pH 7.6) with BNPI C-terminal antiserum diluted 1:6000 for peroxidase and 1:3000 for immunogold labeling, respectively. In tissue that was
prepared for peroxidase labeling, the sections were incubated for 30 min in biotinylated goat anti-rabbit immunoglobulin diluted 1:400 in
0.1% BSA, for 30 min in avidin-biotin peroxidase complex diluted
1:100, and then for 6 min in a solution containing 22 mg of
3,3'-diaminobenzidine and 10 µl of 30% H2O2
in 100 ml of 0.1 M TS, pH 7.6. The sections used for
silver-enhanced immunogold labeling (Chan et al., 1990 ) were incubated
for 2 hr in a 1:50 dilution of colloidal gold (1 nm) conjugated to
anti-rabbit IgG (Amersham), fixed in PBS containing 2% glutaraldehyde
for 10 min, and reacted with a silver solution by using a light stable
intenSEM kit (Amersham) for 5-8 min. The immunolabeled tissue sections were fixed in 2% osmium tetroxide for 60 min, dehydrated in a series
of graded ethanols and propylene oxide, and flat-embedded in Embed 812 between two pieces of Aclar plastic.
Ultrathin sections were collected from the outer surface of the
plastic-embedded tissue with an LKB ultramicrotome. These were taken
from three regions: the stratum lucidum of CA3, the polymorphic or
hilar layer of the dentate gyrus in the dorsal hippocampus, and the
dorsolateral caudate nucleus at the level of the crossing of the
anterior commissure (Paxinos and Watson, 1986 ). The sections were
counterstained with uranyl acetate and lead citrate and then examined
with a Philips electron microscope (Mahwah, NJ).
Primary hippocampal cultures. Hippocampi from E19 Sprague
Dawley rats were dissociated by trypsinization, and the cells were plated on poly-D-lysine-coated coverslips (12 mm in
diameter) at a density of ~300/mm2 in
B27/Neurobasal medium (Brewer et al., 1993 ). After 14 d in vitro the coverslips were dipped in PBS with
Ca2+ and Mg2+, fixed in 4%
paraformaldehyde, washed in PBS, blocked in PBS containing 2% BSA, 1%
fish skin gelatin, and 0.02% saponin (blocking buffer) for 1.5 hr at
RT, and incubated at RT for 1.5 hr or 4°C overnight in primary
antibody diluted in blocking buffer. The primary antibodies included a
monoclonal antibody to synaptophysin (clone SVP-38; Sigma) at a
dilution of 1:100, as well as the C-terminal BNPI polyclonal antiserum
at 1:2000, preadsorbed with LAP as described above. Then the coverslips
were washed with blocking buffer and incubated for 1 hr at RT in goat
anti-mouse or goat anti-rabbit secondary antibodies conjugated to
fluorescein-5-isothiocyanate (FITC) or tetramethyl rhodamine
isothiocyanate fluorophores (ICN Biomedicals, Costa Mesa, CA) diluted
1:100 in blocking buffer. After three washes in blocking buffer (10 min
each) followed by two brief washes in PBS, the coverslips were mounted
with a ProLong Antifade kit (Molecular Probes, Eugene, OR) and viewed
by epifluorescence under oil at 63× magnification.
 |
RESULTS |
To determine the distribution of BNPI, we raised an antibody
to a bacterial fusion protein containing the C terminus of the transporter. The antiserum recognizes a broad ~60 kDa band in COS
cells transfected with rat BNPI cDNA, but not in control cells (Fig.
1A), consistent with
the 560 residue protein predicted by the cDNA (Ni et al., 1994 ). In
addition, the antibody recognizes a single broad ~60 kDa band in
subcellular fractions of rat brain (Fig. 1B);
confirming the specificity of the antibody, preadsorption with the GST
fusion protein used as immunogen prevents the detection of this ~60
kDa species (Fig. 1C). An ~85 kDa immunoreactive species also occurs in both BNPI-transfected and control COS cells, but this
background band does not occur in rat brain. COS cells transfected with
the BNPI cDNA contain additional ~175, 52, and 50 kDa immunoreactive species that do not appear in control cells or in the brain, suggesting that these bands may result only from expression in a heterologous system. Consistent with the brain-specific expression of BNPI, rat
kidney does not express the ~60 kDa immunoreactive species (Fig.
1B). As anticipated for an integral membrane protein,
the ~60 kDa immunoreactive species in brain sediments with membranes in a high-speed pellet (HSP) rather than with soluble proteins in the
high-speed supernatants (HSS1 and HSS2; Fig. 1B).
Furthermore, the inability to pellet a large proportion of BNPI in the
initial low-speed centrifugation (P1) indicates that most of the
transporter in the brain does not associate tightly with the
cytoskeleton.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 1.
BNPI antiserum specifically recognizes a 60 kDa
protein in transfected COS cells and rat brain. A, COS
cells were transfected with rat BNPI cDNA or with vector alone. Equal
amounts of protein from each postnuclear supernatant were separated by
electrophoresis via 10% SDS-polyacrylamide, transferred to
nitrocellulose, and immunoblotted with antiserum generated against the
C terminus of BNPI. The antiserum recognizes a single broad ~60 kDa
band in COS cells expressing BNPI (arrow), but not in
control cells. Note that the ~85 kDa background species detected in
both BNPI-transfected and control cells, as well as the faint ~175,
52, and 50 kDa species present only in BNPI-transfected cells, does not
occur in the brain. B, BNPI antiserum recognizes a
single ~60 kDa species in rat brain (arrow).
Differential centrifugation of rat brain extracts was performed as
described in Materials and Methods, and a Western blot containing equal
amounts of protein from each fraction was immunolabeled by using the
BNPI C-terminal antiserum preadsorbed with a control GST fusion
protein. The homogenate (H) contains an
~60 kDa immunoreactive species. Low-speed centrifugation (1075 × g for 20 min) to remove cell debris
(P1) results in the sedimentation of some immunoreactive
material, but the majority occurs in the postnuclear supernatant
(PNS). Centrifugation of the PNS at
152,000 × gmax for 1 hr sediments BNPI
in the high-speed pellet (HSP), whereas the high-speed
supernatants (HSS1 and HSS2) contain
little immunoreactive material. Postnuclear supernatant from the rat
kidney (40 µg of protein) does not express the ~60 kDa species,
consistent with the brain-specific expression of BNPI. The molecular
weights of standards (in kilodaltons) are shown to the
left. C, Preadsorption of the BNPI
antiserum with the GST fusion protein used as an immunogen prevents
detection of the ~60 kDa species (arrow) in the same
rat brain fractions that were used in B.
|
|
Glutamatergic projections express BNPI
With the use of light microscopy, immunocytochemistry shows the
expression of BNPI protein in gray matter, including cortex and basal
ganglia (Fig. 2A,B).
White matter such as the corpus callosum shows no detectable labeling
for BNPI, consistent with the exclusive expression of BNPI mRNA by
neurons. The cortex does not show a laminar pattern of labeling, and
both cortex and caudate putamen lack immunoreactive cell bodies. Within
the neuropil of the cortex and caudate putamen nucleus, BNPI exhibits a
punctate pattern of immunoreactivity suggestive of neuronal processes
(Fig. 2C,D). Preadsorption of the antibody with the GST
fusion protein used as immunogen completely abolishes the
immunoreactivity in brain sections, confirming the specificity of the
antibody (Fig. 2E).

View larger version (82K):
[in this window]
[in a new window]
|
Figure 2.
BNPI immunohistochemistry at the level of the
basal ganglia. Representative 40 µm coronal sections from rat brain
were immunolabeled for BNPI by using the antiserum preadsorbed with LAP
and either the control GST fusion protein GST-VGAT
(A-D) or GST-BNPI as a control
(E). A, B, Sections through the
basal ganglia show immunoreactivity distributed diffusely throughout
the cortex (Cx) and caudate putamen
(CPu). The cortex lacks a laminar pattern of
immunoreactivity. White matter such as the corpus callosum
(cc) shows little labeling. C, D, At high
magnification, punctate immunoreactivity occurs in nerve fibers within
caudate putamen (C) and cortex
(D). Cell bodies show no labeling.
E, Adsorption of the antibody with GST-BNPI abolishes
immunolabeling (shown here for cortex), confirming the specificity of
the reaction. Scale bars: A, 1 mm; B, 100 µm; C-E, 50 µm.
|
|
Sections through the hippocampus show a distinctive laminar pattern of
immunoreactivity (Fig. 3A,B).
Dense immunoreactivity occurs in the polymorphic and molecular layers
of both the dentate gyrus and the hippocampus proper. Examination of
the CA3 region under higher magnification reveals coarse granular
labeling at the periphery of the pyramidal cell layer (Fig.
3D) strongly suggestive of mossy fiber synapses (Haug et
al., 1971 ; Amaral and Dent, 1981 ). Stratum oriens of CA3 exhibits
weaker but still intense immunoreactivity that occurs in nerve
terminal-like puncta, and stratum radiatum of CA3 shows even less
intense BNPI immunoreactivity (Fig. 3B,D). The results thus
indicate the heterogeneity of BNPI expression at different excitatory
connections. In CA1, strata oriens and radiatum also show diffuse
granular labeling suggestive of BNPI localization to the terminals of
Schaffer collaterals (Fig. 3E), and this labeling
substantially exceeds the labeling observed in stratum lacunosum
moleculare (Fig. 3B), further supporting the heterogeneity
of BNPI expression. In the dentate gyrus the outer two-thirds of the
molecular layer label more strongly for BNPI than does the inner
one-third (Fig. 3B), indicating preferential localization to
the perforant path inputs from the entorhinal cortex relative to inputs
from the ipsilateral associational/commissural projection (Matthews et
al., 1976 ; Johnston and Amaral, 1998 ). Similar to cell bodies in the
cortex and striatum, cell bodies in the hippocampus, including
hippocampal pyramidal cells, dentate gyrus granule cells, and hilar
interneurons, show no detectable BNPI immunoreactivity (Fig.
3B,D,E). Considered as a whole, the distribution of BNPI
immunoreactivity in the hippocampus strongly resembles that for
glutamate, suggesting the preferential expression of BNPI at excitatory
synapses (Storm-Mathisen et al., 1983 ).

View larger version (93K):
[in this window]
[in a new window]
|
Figure 3.
BNPI immunohistochemistry at the level of the
hippocampus. Representative 40 µm coronal sections from rat brain
were immunolabeled for BNPI by using the antiserum preadsorbed with LAP
and either the control GST fusion protein GST-VGAT (A, B, D,
E) or GST-BNPI as a control (C).
A, A section through the hippocampus (Hp) shows
a distinctive pattern of immunoreactivity, particularly within the
molecular and polymorphic layers of the hippocampus. White matter such
as the internal capsule (ic) shows little
labeling. B, Under higher magnification the hippocampus
shows dense immunoreactivity in stratum oriens
(O) and stratum radiatum
(R), with a marked reduction in labeling in
stratum lacunosum moleculare (LM). In the dentate
gyrus the outer two-thirds of the molecular layer
(M) label more strongly for BNPI than the
inner one-third, suggesting preferential localization to excitatory
perforant path inputs from the entorhinal cortex. Strikingly, the
granule cell body layer of the dentate gyrus (G)
and the pyramidal cell body layer (P) of the
hippocampus proper both lack substantial immunoreactivity.
C, Adsorption of the antibody with GST-BNPI abolishes the
immunolabeling, confirming the specificity of the reaction. D,
E, A high-magnification view of CA3 (D)
shows coarse granular labeling in stratum lucidum
(L) at the periphery of the pyramidal cell layer
(P), strongly suggestive of mossy fiber synapses.
Stratum oriens (O) and stratum radiatum
(R) of both CA3 (D) and CA1
(E) show weaker, more diffuse BNPI
immunoreactivity. Scale bars: A, 1 mm; B,
C, 500 µm; D, 100 µm;
E, 50 µm.
|
|
Sections through the midbrain and rostral pons show immunoreactivity
for BNPI in gray matter such as the periaqueductal gray and pontine
nuclei (Fig. 4A). White
matter such as the corticospinal tracts (in the cerebral peduncle), the
decussation of the superior cerebellar peduncle, the lateral lemnisci,
and the lateral tegmental tracts shows no labeling. Similar to other
brain regions, BNPI is not detectable in cell bodies of the substantia
nigra and tectum (Fig. 4B,D). Rather, BNPI
immunoreactivity is distributed uniformly in terminal-like puncta
throughout both regions.

View larger version (80K):
[in this window]
[in a new window]
|
Figure 4.
BNPI immunohistochemistry at the level of the
caudal midbrain. Representative 40 µm coronal sections from rat brain
were immunolabeled for BNPI by using the antiserum preadsorbed with LAP
and either the control GST fusion protein GST-VGAT (A, B,
D) or GST-BNPI as a control (C, E).
A, A section through the rostral pons shows immunoreactivity in
gray matter of the periaqueductal gray (PAG) and
particularly strong labeling in the pontine nuclei (Pn).
White matter such as the corticospinal tracts in the cerebral peduncle
(cp), the decussation of the superior cerebellar
peduncle (xscp), the lateral lemnisci
(ll), and the lateral tegmental tracts
(ltg) shows little labeling. B, D,
Sections through the midbrain observed under high magnification show
uniform punctate immunoreactivity in the neuropil of the substantia
nigra (B) and tectum (D).
Cell bodies in both regions show no labeling. C, E,
Adsorption of the antibody with GST-BNPI abolishes the majority of
punctate immunoreactivity in the substantia nigra
(C) and tectum (E),
confirming the specificity of the reaction. Scale bars:
A, 1 mm; B-E, 50 µm.
|
|
In the cerebellum, BNPI immunoreactivity has a laminar
distribution (Fig. 5A,B). The
molecular layer shows dense punctate labeling suggestive of
localization to climbing or parallel fibers that synapse onto Purkinje
cell dendrites (Fig. 5D). Within the granule cell layer,
BNPI immunoreactivity appears much less dense but has a punctate
appearance similar to that observed in the molecular layer. These large
punctate structures strongly resemble the rosettes formed by excitatory
mossy fiber terminals on granule cells (Palay and Chan-Palay, 1974 ;
Llinás and Walton, 1998 ). The pattern of labeling does not
resemble that observed for inhibitory connections made by GABAergic
cells (Esclapez et al., 1994 ; Chaudhry et al., 1998 ), further
supporting the specific localization of BNPI to excitatory terminals.
As in other brain regions, cell bodies in the cerebellum, including
granule and Golgi cells of the granule layer, basket and stellate cells
of the molecular layer, and Purkinje cells, show no immunoreactivity
for BNPI (Fig. 5D).

View larger version (78K):
[in this window]
[in a new window]
|
Figure 5.
BNPI immunohistochemistry at the level of the
medulla and cerebellum. Representative 40 µm coronal sections from
rat brain were immunolabeled for BNPI by using the antiserum
preadsorbed with LAP and either the control GST fusion protein GST-VGAT
(A, B, D) or GST-BNPI as a control
(C). A, A section through the
cerebellum (Cb) shows prominent immunoreactivity in
cerebellar cortex. B, A high-magnification view of the
cerebellar cortex reveals strong dense labeling in the molecular layer
(MO) and lighter labeling in the granule cell layer
(GC). C, Adsorption of the antibody with
GST-BNPI abolishes the immunolabeling, confirming the specificity of
the reaction. D, At high magnification the granule cell
layer (GC) shows large punctate structures
characteristic of mossy fiber synapses onto granule cells. Within the
molecular layer (MO) the immunoreactivity produces a
dense coarse labeling pattern suggestive of climbing or parallel fiber
synapses onto Purkinje cell dendrites. Cell bodies, including Purkinje
cells (PC), granule and Golgi cells, and basket
and stellate cells, show no immunoreactivity. Scale bars:
A, 1 mm; B, C, 500 µm;
D, 50 µm.
|
|
BNPI localizes to nerve terminals in hippocampal cultures
To determine whether BNPI localizes to nerve terminals, we
immunolabeled 2-week-old primary hippocampal cultures with antibodies to both BNPI and the synaptic vesicle marker synaptophysin (Jahn et
al., 1985 ). Similar to synaptophysin (Fig.
6A,C), BNPI distributes in a punctate pattern along neuronal processes within the cultures (Fig. 6B,D). Double labeling confirms that BNPI
colocalizes with synaptophysin (Fig. 6). However, many varicosities
that contain synaptophysin lack detectable BNPI, indicating that BNPI
localizes only to a subset of nerve terminals. Some neuronal cell
bodies also stain weakly for BNPI, and all of these cell bodies stain for the phosphate-activated glutaminase, PAG (data not shown), a
protein highly expressed in many glutamatergic neurons (Najlerahim et
al., 1990 ; Aoki et al., 1991 ; Kaneko and Mizuno, 1994 ; Torgner et al.,
1998 ).

View larger version (70K):
[in this window]
[in a new window]
|
Figure 6.
BNPI colocalizes with synaptophysin at a subset of
varicosities in primary hippocampal cultures. After 14 d in
vitro, primary hippocampal cultures from E19 rats were
double-labeled for the synaptic vesicle marker synaptophysin (A,
C) and BNPI (B, D). Synaptophysin was detected
with a mouse monoclonal antibody and BNPI with the rabbit polyclonal
antibody. The primary antibodies were recognized with appropriate
secondary antibodies conjugated to rhodamine (A, C) and
fluorescein (B, D). Examination of two fields (A,
B and C, D) shows that synaptophysin distributes
in a punctate manner along neuronal processes (arrows).
Essentially all BNPI immunoreactivity distributes in a similar manner,
colocalizing with synaptophysin at synaptic structures
(arrows). However, many synaptophysin-immunoreactive
synapses do not label for BNPI (arrowheads), indicating
that BNPI localizes to a subset of terminals. Scale bars, 20 µm.
|
|
Localization of BNPI to synaptic vesicles at
excitatory synapses
To determine the subcellular localization of BNPI, we used
electron microscopic immunolabeling. As a confirmation of the light microscopic analysis of the hippocampus, electron microscopic immunoperoxidase labeling in stratum lucidum of CA3 shows prominent reaction product in large axon terminals having the morphological characteristics of mossy fiber boutons (Fig.
7A) (Amaral and Dent, 1981 ).
In the hilar layer of the dentate gyrus, where mossy fiber collaterals
terminate, a few large terminals similar to those in the CA3 region
contain BNPI immunoreactivity (data not shown). Many smaller terminals
in the dentate gyrus that form asymmetric excitatory-type synapses with
dendritic spines also label for BNPI (Fig. 7B). Thus, except
for rare dendritic spines and isolated glial processes, BNPI localizes
exclusively to axon terminals.

View larger version (125K):
[in this window]
[in a new window]
|
Figure 7.
BNPI localizes to excitatory-type terminals in the
rat hippocampal formation and caudate putamen nucleus.
A, In stratum lucidum of the CA3 region of the hippocampus,
BNPI peroxidase labeling is seen in a large, complex mossy fiber
terminal that contacts an unlabeled spine (US). Although
this section does not demonstrate unequivocally the asymmetric nature
of the synapse, all mossy fiber terminals form exclusively asymmetric
synapses onto dendritic spines (Amaral and Dent, 1981 ). Within the
mossy fiber terminal the peroxidase reaction product is distributed
diffusely around the membranes of numerous small synaptic vesicles
(SSV). Intense labeling also occurs near the
plasma membrane (arrowheads), where it appears to
overlie large dense core vesicles. B, In the hilar layer
of the dentate gyrus, several small axon terminals
(BNPI-t) contain peroxidase labeling for BNPI that is
associated with putative dense core vesicles near the plasma membrane
(arrowheads). One of these labeled terminals forms an
asymmetric synapse (open arrow) with an unlabeled spine.
Many unlabeled spines and unlabeled axon terminals are seen in the
neuropil. One of the unlabeled terminals (UT)
forms an asymmetric synapse (open arrow) with an
unlabeled spine (US). C, Intense
peroxidase reaction product surrounds the membranes of small vesicles
in selected unmyelinated axons (BNPI-a) and two axon
terminals (BNPI-t) in the dorsal caudate putamen
nucleus. Numerous other unlabeled axons and nerve terminals
(UT) are present in the neuropil. The unlabeled
terminal (UT) on the right forms
an asymmetric synapse (open arrowhead) with an unlabeled
dendritic spine (US). Scale bars, 0.5 µm.
|
|
Nerve terminals in the hippocampus show heterogeneous expression of
BNPI. In processes in which membrane specializations are observed, the
labeled terminals form asymmetric synapses with unlabeled dendritic
spines (Fig. 7B). Symmetric synapses do not contain
detectable BNPI (data not shown), supporting a specific role for the
protein in excitatory transmission. In addition, many terminals forming
asymmetric synapses do not contain detectable BNPI, indicating
expression only at a subset of excitatory synapses (Fig.
7B). Within the labeled terminals the peroxidase reaction product distributes diffusely along the membranes of small synaptic vesicles (Fig. 7A,B). Intense reaction product also
associates with the dense core vesicles found in mossy fiber terminals
of CA3 (Fig. 7A) and in terminals within the hilar region of
the dentate gyrus (Fig. 7B). BNPI therefore appears to
localize to specialized secretory vesicles within a subset of
excitatory nerve terminals.
We also have used electron microscopic immunoperoxidase labeling to
examine the distribution of BNPI in the dorsal caudate putamen nuclei
(Fig. 7C). Reaction product densely distributes to nerve
terminals and small unmyelinated axons adjacent to other unlabeled
processes. As in the hippocampus the terminals forming asymmetric
synapses show intense labeling, but symmetric synapses contain no
reaction product (data not shown). Within the labeled nerve terminals
and axons, BNPI immunoreactivity surrounds the membranes of small
vesicles (Fig. 7C).
Because the immunoperoxidase method cannot resolve the precise
subcellular location of BNPI, we used electron microscopic labeling
with immunogold-silver (Fig. 8). Similar
to the peroxidase reaction product, silver-intensified immunogold
particles localize to nerve terminals only at asymmetric synapses in
the caudate putamen. However, not all terminals forming asymmetric
synapses were labeled, and some of these unlabeled terminals form
asymmetric synapses onto the same dendrites that receive input from
BNPI-labeled terminals. Within the labeled terminals, BNPI localizes to
the membrane of small synaptic vesicles. The labeling appears more intense over synaptic vesicles distant from the active zone, although we did not evaluate this rigorously. In addition, a few gold particles directly contact the plasma membrane, but only in the vicinity of
synaptic vesicles at regions of the terminal distant from the active
zone. Therefore, despite the Na+ dependence of BNPI
activity, BNPI localizes predominantly to synaptic vesicles at
asymmetric excitatory-type synapses.

View larger version (198K):
[in this window]
[in a new window]
|
Figure 8.
BNPI localizes to synaptic vesicles at asymmetric
synapses by immunogold-silver electron microscopy. Immunogold-silver
electron microscopy localizes BNPI in axon terminals that form
asymmetric excitatory-type synapses (open arrowheads)
with unlabeled dendritic shafts (UD) or spines
(US) in the rat caudate putamen nucleus.
A, Immunogold-silver deposits are seen in direct contact with
many small synaptic vesicles (SSV) within the
BNPI-labeled terminals. Several gold particles also directly contact
the plasma membrane (arrowheads) but only in the
vicinity of synaptic vesicles. B, Immunogold-silver
labeling for BNPI is associated with SSVs in two axon terminals, one of
which forms an asymmetric synapse (open arrowhead) with
a spine from the unlabeled dendrite (UD). An adjacent
unlabeled terminal (UT) also forms an asymmetric
synaptic contact (open arrowhead) with the shaft of the
same dendrite. Scale bars, 0.5 µm.
|
|
Biochemical fractionation demonstrates BNPI on
synaptic vesicles
Because either the tissue preparation required for immunoelectron
microscopy or the interaction of BNPI with another protein may limit
the access of BNPI antibody at sites such as the plasma membrane, we
also examined the distribution of the transporter, using biochemical
methods. Biochemical fractionation followed by immunoblot analysis
obviates problems related to fixation or protein interaction and hence
may identify plasma membrane BNPI not detectable by immunoelectron
microscopy.
To distinguish synaptic vesicles from plasma membrane, we first
prepared synaptosomes from the rat cortex. BNPI initially sediments
with plasma membrane proteins such as the
Na+/K+ ATPase and syntaxin
(Bennett et al., 1993 ) in the insoluble debris (P1) and in the crude
synaptosomal pellets, P2 and P2' (Fig.
9A). However, the synaptic
vesicle protein synaptophysin also appears in these same fractions.
After hypo-osmotic lysis of the synaptosomes, Na+/K+ ATPase and syntaxin
sediment with the heavy lysed synaptosomal membranes (LP1), whereas
BNPI and synaptophysin fractionate together into the lighter membrane
fractions, LS1 and LP2 (Fig. 9A). Thus, BNPI cofractionates
with synaptic vesicles by differential centrifugation.

View larger version (25K):
[in this window]
[in a new window]
|
Figure 9.
BNPI resides on synaptic vesicles by differential
centrifugation and velocity sedimentation. A,
Synaptosomes and synaptic vesicles were prepared from rat brain. Equal
amounts of protein from each fraction were loaded into lanes and
analyzed by Western analysis. BNPI appears in both the insoluble debris
(P1) and postnuclear supernatant (S1).
Further, BNPI sediments with the plasma membrane marker
Na+/K+-ATPase, the synaptic
vesicle marker synaptophysin, and the presynaptic plasma membrane
marker syntaxin in the crude synaptosomal fractions P2
and P2' rather than with the high-speed supernatants
S2 and S2'. After hypo-osmotic lysis of
the synaptosomes, the
Na+/K+-ATPase and syntaxin occur
principally in LP1, strongly suggesting the localization
of plasma membrane fragments to this fraction. In contrast, the first
supernatant (LS1) contains more BNPI and synaptophysin
than the first pellet (LP1), suggesting localization of
BNPI to synaptic vesicles. Further, high-speed sedimentation of
LS1 shows localization of both BNPI and synaptophysin to
LP2 rather than to LS2. Thus, BNPI
cofractionates with synaptophysin rather than with the plasma membrane
markers, suggesting localization to a population of synaptic
vesicles. B, Fractions 1-11 were collected from the top
of a 5-25% glycerol velocity gradient of LS1. Western analysis of
equal volumes of each fraction shows that BNPI cofractionates with
synaptophysin in the middle of the gradient. In contrast, the synaptic
plasma membrane marker syntaxin occurs predominantly at the bottom of
the gradient. Thus, BNPI occurs on synaptic vesicles rather than on the
presynaptic plasma membrane. The small amount of syntaxin
cofractionating with synaptophysin presumably reflects the low levels
of syntaxin known to occur on synaptic vesicles.
|
|
Velocity sedimentation through glycerol separates synaptic vesicles
from essentially all other membranous organelles (Clift-O'Grady et
al., 1990 ). We used LS1 as the starting material because it contains
synaptic vesicles (Fig. 9A), and sedimentation through glycerol shows that BNPI cofractionates with synaptophysin in the
middle of the gradient (Fig. 9B). The synaptic plasma
membrane protein syntaxin resides predominantly in heavy membranes but also occurs at low levels on synaptic vesicles (Fig. 9B)
(Walch-Solimena et al., 1995 ). Importantly, the heavy membrane
fractions contain very little BNPI when compared with the synaptic
vesicle fractions, indicating extremely low levels of expression at the
plasma membrane. Thus, BNPI localizes to synaptic vesicles by
biochemical fractionation as well as by immunoelectron microscopy.
 |
DISCUSSION |
The antibody to BNPI that we describe here specifically recognizes
a protein of the anticipated size in both transfected cells and the rat
brain. Although rat kidney expresses distinct
Na+-dependent Pi transporters (Li and
Xie, 1995 ), their sequences diverge substantially from BNPI at the C
terminus used to produce antigen, making it unlikely that the BNPI
antibody cross-reacts with these proteins.
BNPI localizes to nerve terminals at excitatory synapses
The results indicate that BNPI localizes to nerve terminals. By
light microscopy it has been shown that the BNPI antibody selectively
labels structures that resemble nerve terminals and does not label cell
bodies or dendritic structures. Electron microscopy confirms the
presynaptic expression of BNPI. Further, essentially all BNPI
immunoreactivity colocalizes with that of synaptophysin in primary
hippocampal cultures. However, many varicosities in the cultures
express synaptophysin, but not BNPI. BNPI thus appears to localize only
to a subset of nerve terminals.
Previous in situ hybridization localizing BNPI to a subset
of cell groups in the brain (Ni et al., 1995 ) was consistent with the
expression of BNPI mRNA by glutamatergic neurons. Localization of BNPI
protein now indicates a specific role in glutamatergic transmission.
The outer two-thirds of the molecular layer in the dentate gyrus show
strong immunoreactivity, suggesting the expression of BNPI by
glutamatergic inputs from the perforant pathway (Matthews et al., 1976 ;
Johnston and Amaral, 1998 ). Indeed, the entorhinal cortex, which gives
rise to the perforant path, expresses substantial amounts of BNPI mRNA.
Light and electron microscopy show that BNPI localizes to excitatory
mossy fiber terminals in stratum lucidum of CA3 of the hippocampus,
consistent with the expression of BNPI mRNA by dentate gyrus granule
cells (Ni et al., 1995 ). In addition, BNPI localizes to excitatory
Schaffer collaterals in strata oriens and radiatum of CA1, and the
hippocampal neurons in CA3 from which these collaterals derive express
BNPI mRNA (Ni et al., 1995 ). The laminar pattern of BNPI
immunoreactivity in the hippocampus strongly resembles that previously
observed for glutamate (Storm-Mathisen et al., 1983 ). Further, electron
microscopic immunolabeling confirms that high levels of BNPI occur at
asymmetric excitatory-type terminals in both the hippocampus and
caudate putamen nuclei, strongly supporting a role for BNPI in
excitatory transmission. Additionally, in hippocampal cultures the
neuronal cell bodies express low levels of BNPI, and all of the
immunoreactive cells also express PAG, a protein essentially restricted
to glutamatergic neurons (Najlerahim et al., 1990 ; Aoki et al., 1991 ;
Kaneko and Mizuno, 1994 ; Torgner et al., 1998 ).
BNPI protein also localizes to excitatory connections in the
cerebellum. Excitatory synapses made by climbing and parallel fiber
inputs onto Purkinje cell dendrites occur in the molecular layer, and
the molecular layer contains high levels of BNPI, consistent with the
expression of BNPI mRNA by inferior olivary neurons and granule cells
from which climbing and parallel fibers arise. In the granule cell
layer the excitatory mossy fiber terminals, which derive from pontine
nuclei expressing BNPI mRNA, also label heavily for BNPI. Thus, BNPI
protein occurs at glutamatergic synapses (Storm-Mathisen and Ottersen,
1988 ) in multiple brain regions.
The results also indicate that BNPI does not function in inhibitory
transmission. By light microscopy it has been shown that BNPI
immunoreactivity differs dramatically from that of GABA and such
GABAergic markers as glutamic acid decarboxylase and the vesicular GABA
transporter (Storm-Mathisen and Ottersen, 1983 ; Esclapez et al., 1994 ;
Chaudhry et al., 1998 ). Consistent with this observation, inhibitory
cell populations express no BNPI mRNA (Ni et al., 1995 ). Electron
microscopy confirms that symmetric, presumably inhibitory, synapses do
not express detectable BNPI protein. BNPI immunoreactivity in such
regions as the caudate putamen that contain abundant GABAergic
neurons thus presumably derives from other brain regions, such as
the cortex, which do express BNPI mRNA (Ni et al., 1995 ).
Although restricted to glutamatergic terminals, BNPI expression does
not occur at all glutamatergic synapses. In stratum lucidum of the CA3
region of the hippocampus, structures having the light microscopic
features of mossy fiber terminals show strong immunoreactivity for
BNPI. However, Schaffer collaterals in strata oriens and radiatum of
both CA3 and CA1 show much less intense immunoreactivity, indicating heterogeneity of BNPI expression by glutamatergic afferents. Consistent with these observations, thalamic nuclei use glutamate as their neurotransmitter but conspicuously lack BNPI mRNA (Ni et al., 1995 ).
Electron microscopic immunolabeling of both the hippocampus and caudate
putamen also shows many nerve terminals forming asymmetric synapses
that do not contain BNPI. Thus, BNPI appears to have a specific role
only at certain excitatory synapses.
Potential physiological roles for BNPI at excitatory synapses
Plasma membrane Pi transport mediated by BNPI may
maintain the level of ATP required for neuronal function (Glinn et al., 1995 , 1997 ). Indeed, a substantial proportion of externally applied 32Pi incorporates into ATP after
Na+-dependent uptake into cultured cortical neurons,
and the levels of ATP, NADPH, and intracellular-free Pi in
these cells also depend on extracellular Pi. However, the
restricted expression of BNPI to particular neuronal populations
suggests that BNPI does not have a general role in neuronal function.
Rather, BNPI appears to function specifically in a subset of excitatory
neurons. Further, the presynaptic localization of BNPI suggests a role
in the regulation of glutamate synthesis, accumulation, or release.
Although BNPI belongs to a family of Na+-dependent
Pi transporters, it shows particularly strong sequence
similarity to EAT-4, a C. elegans gene product recently
implicated in glutamatergic neurotransmission. Originally isolated in
screens for genes involved in feeding (Avery, 1993 ), eat-4
mutants show defects in a number of behaviors, many of which involve
the transmitter glutamate (Raizen and Avery, 1994 ; Dent et al., 1997 ;
Li et al., 1997 ; Lee, Sawin, Chalfie, Horvitz, and Avery, unpublished
observations). However, the iontophoretic application of glutamate at a
glutamatergic synapse elicits a normal postsynaptic response (Dent et
al., 1997 ; Li et al., 1997 ), strongly suggesting a specific presynaptic
role for BNPI. Importantly, neurotransmission by serotonin,
acetylcholine, and GABA appears normal in eat-4 mutants
(Lee, Sawin, Chalfie, Horvitz, and Avery, unpublished observations).
Thus, both EAT-4 and its vertebrate homolog BNPI appear to have a
specific presynaptic function at glutamatergic connections.
How does BNPI influence glutamate release? BNPI may function
specifically in glutamate transport, but a large family of plasma membrane glutamate transporters has been identified already (Arriza et
al., 1994 ; Robinson and Dowd, 1997 ), and BNPI shows no sequence similarity to these proteins. Although the proteins responsible for
vesicular glutamate transport have not yet been identified and we find
that BNPI localizes to synaptic vesicles, BNPI clearly functions as a
Pi transporter (Ni et al., 1994 , 1996 ). Furthermore, the
dependence on Na+ makes it unlikely that BNPI
functions in vesicles, where a proton electrochemical gradient provides
the principal driving force for the packaging of classical
neurotransmitters (for review, see Liu and Edwards, 1997 ). It seems
more likely that BNPI contributes to the synthesis of glutamate at the
nerve terminal.
An isoform of the enzyme glutaminase synthesizes a majority of the
glutamate available for Ca2+-dependent synaptic
release (Bradford et al., 1978 ; Hamberger et al., 1979a ,b ; Ward et al.,
1983 ; Szerb and O'Regan, 1985 ). This glutaminase localizes to a subset
of glutamatergic fibers (Aoki et al., 1991 ; Kaneko and Mizuno, 1994 ;
Torgner et al., 1998 ). Within neurons, the glutaminase associates with
mitochondria and synaptic vesicles (Aoki et al., 1991 ) and also occurs
in a soluble form (Torgner et al., 1998 ). Interestingly, Pi
prominently activates this glutaminase, accounting for its designation
as PAG (EC 3.5.1.2) (Curthoys and Watford, 1995 ). Because PAG
has a K1/2 for Pi of 10-25
mM, physiological changes in cytoplasmic Pi
have the potential to regulate PAG activity (for review, see Erecinska and Silver, 1990 ). CSF contains ~100-fold lower levels of
Pi (Fishman, 1992 ) than the
K1/2 for Pi,
suggesting that the active accumulation of Pi catalyzed by
BNPI may elevate cytoplasmic levels substantially. BNPI therefore may
regulate glutamate synthesis and release. This role is consistent with
both the glutamatergic phenotype of the eat-4 mutant in
C. elegans and the localization of vertebrate BNPI to
excitatory nerve terminals.
In addition to glutamate, PAG produces ammonia. In the kidney, PAG
contributes to the elimination of acid from the body by producing
ammonia, which diffuses into the lumen of the nephron and buffers the
protons secreted into the urine (Lote, 1994 ; Curthoys and Watford,
1995 ). Protonation of ammonia in the lumen of the nephron yields
ammonium ions for which the charge prevents diffusion back across the
renal epithelium. Similarly, the ammonia produced by PAG in
glutamatergic neurons may diffuse into synaptic vesicles, and the
protonation occurring in this acidic compartment presumably would
prevent diffusion back to the cytoplasm. Ammonia produced by PAG thus
may reduce the pH gradient across the vesicle membrane and increase the
electrical component of the proton electrochemical gradient.
Importantly, the transport of glutamate into synaptic vesicles differs
from the transport of other classical transmitters: glutamate transport
depends more on the electrical component of the proton electrochemical
gradient than on the pH gradient (Maycox et al., 1988 ; Carlson et al.,
1989 ). PAG therefore has the potential to facilitate glutamate release
by producing ammonia as well as glutamate.
Localization of BNPI to synaptic vesicles suggests regulation of
BNPI function
Although its dependence on Na+ suggests that
BNPI functions at the plasma membrane, the results indicate that the
majority of BNPI resides on synaptic vesicles. Immunoelectron
microscopy demonstrates that the vast majority of BNPI localizes to
synaptic vesicles in axon terminals forming asymmetric synapses. In
addition, the localization of BNPI to synaptic vesicles by biochemical
methods excludes the possibility that we have failed to detect BNPI at the plasma membrane because of problems associated with fixation or
protein-protein interactions. Because the dependence of BNPI on a
Na+ rather than H+ gradient makes
it unlikely that the transporter functions in synaptic vesicles, we
presume that the localization to synaptic vesicles provides a mechanism
for precisely regulated cell-surface expression and function. In
particular, the appearance of BNPI at the plasma membrane on synaptic
vesicle exocytosis would allow neural activity to increase glutamate
synthesis via the activation of PAG. Interestingly, unlike neuronal
populations that use other neurotransmitters, glutamatergic neurons
appear to lack a presynaptic reuptake system to replenish released
transmitter (Rothstein et al., 1994 ; Lehre et al., 1995 ;
Velaz-Faircloth et al., 1996 ; Arriza et al., 1997 ). BNPI therefore may
provide an alternative mechanism to replenish glutamate stores after
massive exocytosis. The low steady-state level of BNPI at the plasma
membrane also suggests that protracted increases in cytoplasmic
Pi, and hence glutamate synthesis, may be
deleterious.
In conclusion, we show that BNPI localizes specifically to the
presynaptic element at excitatory synapses, consistent with the defect
in glutamate release observed in eat-4 mutants in C. elegans. Although the function of BNPI in glutamatergic
transmission remains unknown, BNPI may serve to stimulate
phosphate-activated glutaminase and hence increase the synthesis of
glutamate. Surprisingly, BNPI resides on synaptic vesicles rather than
on the plasma membrane, suggesting precise temporal regulation of its
cell-surface expression and function by neural activity.
 |
FOOTNOTES |
Received May 15, 1998; revised Aug. 6, 1998; accepted Aug. 17, 1998.
This work was supported by Grants MH00078 and MH40342 from the National
Institute of Mental Health (to V.M.P.), by a Howard Hughes Predoctoral
Fellowship (to E.E.B.), and by National Institute of Mental Health
Grant MH01365 and National Institute of Neurological Diseases and
Stroke Grant NS16033 (to R.H.E.). We thank R. Y. N. Lee and L. Avery for thoughtful discussion and for communicating unpublished observations; S. E. Craven and D. S. Bredt for
assistance with the hippocampal cultures; F. Chaudhry, H. J. Ralston III, and D. H. Lowenstein for help with the anatomy;
R. J. Reimer for help with the graphics and review of this
manuscript; and the members of the Edwards lab for technical assistance
and thoughtful discussion.
Correspondence should be addressed to Dr. Robert H. Edwards,
Departments of Neurology and Physiology, University of California San
Francisco School of Medicine, 513 Parnassus Avenue, Box 0435, San
Francisco, CA 94143-0435.
 |
REFERENCES |
-
Amaral DG,
Dent JA
(1981)
Development of the mossy fibers of the dentate gyrus. I. A light and electron microscopic study of the mossy fibers and their expansions.
J Comp Neurol
195:51-86[ISI][Medline].
-
Aoki C,
Kaneko T,
Starr A,
Pickel VM
(1991)
Identification of mitochondrial and non-mitochondrial glutaminase within select neurons and glia of rat forebrain by electron microscopic immunocytochemistry.
J Neurosci Res
28:531-548[ISI][Medline].
-
Arriza JL,
Fairman WA,
Wadiche JI,
Murdoch GH,
Kavanaugh MP,
Amara SG
(1994)
Functional comparison of three glutamate transporter subtypes cloned from human motor cortex.
J Neurosci
14:5559-5569[Abstract].
-
Arriza JL,
Eliasof S,
Kavanaugh MP,
Amara SG
(1997)
Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance.
Proc Natl Acad Sci USA
94:4155-4160[Abstract/Free Full Text].
-
Avery L
(1993)
The genetics of feeding in Caenorhabditis elegans.
Genetics
133:897-917[Abstract].
-
Bennett MK,
Garcia-Arraras JE,
Elferink LA,
Peterson K,
Fleming AM,
Hazuka CD,
Scheller RH
(1993)
The syntaxin family of vesicular transport receptors.
Cell
74:863-873[ISI][Medline].
-
Bradford HF,
Ward HK,
Thomas AJ
(1978)
Glutamine
a major substrate for nerve endings.
J Neurochem
30:1453-1459[ISI][Medline]. -
Brewer GJ,
Torricelli JR,
Evege EK,
Price PJ
(1993)
Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination.
J Neurosci Res
35:567-576[ISI][Medline].
-
Caldwell PC,
Lowe AG
(1970)
The influx of orthophosphate into squid giant axons.
J Physiol (Lond)
207:271-280[Abstract/Free Full Text].
-
Carlson MD,
Kish PE,
Ueda T
(1989)
Characterization of the solubilized and reconstituted ATP-dependent vesicular glutamate uptake system.
J Biol Chem
264:7369-7376[Abstract/Free Full Text].
-
Chan J,
Aoki C,
Pickel VM
(1990)
Optimization of differential immunogold-silver and peroxidase labeling with maintenance of ultrastructure in brain sections before plastic embedding.
J Neurosci Methods
33:113-127[ISI][Medline].
-
Chaudhry FA, Reimer RJ, Bellocchio EE, Danbolt NC, Osen KK, Edwards RH,
Storm-Mathisen J (1998) The putative vesicular GABA
transporter "VGAT" localizes to synaptic vesicles in sets of
glycinergic as well as GABAergic neurons. J Neurosci, in
press.
-
Clift-O'Grady L,
Linstedt AD,
Lowe AW,
Grote E,
Kelly RB
(1990)
Biogenesis of synaptic vesicle-like structures in a pheochromocytoma cell line PC-12.
J Cell Biol
110:1693-1703[Abstract/Free Full Text].
-
Curthoys NP,
Watford M
(1995)
Regulation of glutaminase activity and glutamine metabolism.
Annu Rev Nutr
15:133-159[ISI][Medline].
-
Dent JA,
Davis MW,
Avery L
(1997)
avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans.
EMBO J
16:5867-5879[ISI][Medline].
-
Erecinska M,
Silver IA
(1990)
Metabolism and role of glutamate in mammalian brain.
Prog Neurobiol
35:245-296[ISI][Medline].
-
Esclapez M,
Tillakaratne NJK,
Kaufman DL,
Tobin AJ,
Houser CR
(1994)
Comparative localization of two forms of glutamic acid decarboxylase and their mRNAs in rat brain supports the concept of functional differences between the forms.
J Neurosci
14:1834-1855[Abstract].
-
Finn III JP,
Edwards RH
(1997)
Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2.
J Biol Chem
272:16301-16307[Abstract/Free Full Text].
-
Fishman RA
(1992)
Composition of the cerebrospinal fluid.
In: Cerebrospinal fluid in diseases of the nervous system, p 250. Philadelphia: Saunders.
-
Furman S,
Lichtstein D,
Ilani A
(1997)
Sodium-dependent transport of phosphate in neuronal and related cells.
Biochim Biophys Acta
1325:34-40[Medline].
-
Glinn M,
Ni B,
Paul SM
(1995)
Characterization of Na+-dependent phosphate uptake in cultured fetal rat cortical neurons.
J Neurochem
65:2358-2365[ISI][Medline].
-
Glinn M,
Ni B,
Paul SM
(1997)
Inorganic phosphate enhances phosphonucleotide concentrations in cultured fetal rat cortical neurons.
Brain Res
757:85-92[ISI][Medline].
-
Hamberger AC,
Chiang GH,
Nylen ES,
Scheff SW,
Cotman CW
(1979a)
Glutamate as a CNS transmitter. I. Evaluation of glucose and glutamine as precursors for the synthesis of preferentially released glutamate.
Brain Res
168:513-530[ISI][Medline].
-
Hamberger A,
Chiang GH,
Sandoval E,
Cotman CW
(1979b)
Glutamate as a CNS transmitter. II. Regulation of synthesis in the releasable pool.
Brain Res
168:531-541[ISI][Medline].
-
Haug FMS,
Blackstad TW,
Simonsen AH,
Zimmer J
(1971)
Timm's sulfide silver reaction for zinc during experimental anterograde degeneration of hippocampal mossy fibers.
J Comp Neurol
142:22-32.
-
Huttner WB,
Schiebler W,
Greengard P,
De Camilli P
(1983)
Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation.
J Cell Biol
96:1374-1388[Abstract/Free<
|